With rapid advances in nanomedicine, lipid–polymer hybrid nanoparticles (LPHNPs) have emerged as promising nanocarriers for several biomedical applications, including therapeutics delivery and biomedical imaging. Significant research has been dedicated to biomimetic or targeting functionalization, as well as controlled and image-guided drug-release capabilities. Despite this research, the clinical translation of LPHNP-mediated therapeutics delivery has progressed incrementally. In this review, we discuss the recent advances in and challenges to the development and application of LPHNPs, present examples to demonstrate the advantages of LPHNPs in therapeutics delivery and imaging applications, and discuss the translational obstacles to LPHNP technology.

随着纳米医学的飞速发展，脂质-聚合物杂化纳米颗粒（LPHNPs）已成为具有前景的纳米载体，可用于多种生物医学应用，包括治疗药物递送和生物医学成像。大量的研究致力于仿生或靶向功能化，以及受控和图像引导的药物释放功能。尽管进行了这项研究，但LPHNP介导的治疗方法的临床翻译却在逐步发展。在这篇综述中，我们讨论了LPHNPs的开发和应用的最新进展和挑战，并举例说明了LPHNPs在治疗剂递送和成像应用中的优势，并讨论了LPHNP技术的翻译障碍。